Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

TONIX Closes PK Study On New Formulation Of TNX-102 For Fibromyalgia

Tonix Pharmaceuticals Holding Corp (TNXP.OB), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system or "CNS", said that it completed a pharmacokinetic or PK study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome or "FM".

The company noted that the study results support further development of TNX-102 as a product that can potentially deliver benefits similar to those observed in FM patients treated with very low dose cyclobenzaprine in the Company's dose-escalating Phase 2a study.

TONIX said that it is developing new formulations of cyclobenzaprine that are designed for bedtime use. The Company is investigating different technologies to improve the absorption of cyclobenzaprine. The technology applied in this study involves a mixture of cyclobenzaprine and lipids that the Company obtained from Lipocine, Inc. and is designated TNX-102 2.4 mg promicellar gelatin capsules, or gelcaps.

TONIX said that it is on track to initiate a pivotal efficacy study with the final formulation of TNX-102 in the first quarter of 2013.

Register
To receive FREE breaking news email alerts for and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The South Korean government said Thursday it will increase the budget spending next year and run a wider fiscal deficit than expected to bolster economic growth that faces challenges from slow global recovery and weak domestic demand. Government spending will rise by 5.7 percent to KRW 376 trillion the next year, the finance ministry said in its budget proposals. Stocks saw some volatility following the release of the Federal Reserve's monetary policy announcement on Wednesday but managed to end the day modestly higher. With the upward move, the Dow reached a new record closing high. President Barack Obama sought to emphasize in remarks on Wednesday that the American forces being deployed as part of the fight against the terrorist group ISIS will not have a combat mission.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.